TY - JOUR AU - Sean I. Tracy, AU - Thomas M. Habermann, AU - Andrew L. Feldman, AU - Matthew J. Maurer, AU - Ahmet Dogan, AU - Usha S. Perepu, AU - Sergei Syrbu, AU - Stephen M. Ansell, AU - Carrie A. Thompson, AU - George J. Weiner, AU - Grzegorz S. Nowakowski, AU - Cristine Allmer, AU - Susan L. Slager, AU - Thomas E. Witzig, AU - James R. Cerhan, AU - Brian K. Link, PY - 2018/01/31 Y2 - 2024/03/28 TI - Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression JF - Haematologica JA - haematol VL - 103 IS - 2 SE - Articles DO - 10.3324/haematol.2017.176511 UR - https://haematologica.org/article/view/8352 SP - 297-303 AB - The prevalence, presenting clinical and pathological characteristics, and outcomes for patients with diffuse large B-cell lymphoma that is Epstein-Barr virus positive remain uncertain as does the impact of congenital or iatrogenic immunosuppression. Patients with newly diagnosed diffuse large B-cell lymphoma with available tissue arrays were identified from the University of Iowa/Mayo Clinic Molecular Epidemiology Resource. Patients infected with human immunodeficiency virus or who had undergone a prior organ transplant were excluded. Epstein-Barr virus-associated ribonucleic acid testing was performed on all tissue arrays. A history of significant congenital or iatrogenic immunosuppression was determined for all patients. At enrollment, 16 of the 362 (4.4%) biopsies were positive for Epstein-Barr virus. Thirty-nine (10.8%) patients had a significant history of immunosuppression. Patients with Epstein-Barr-positive diffuse large B-cell lymphoma had no unique clinical characteristics but on pathology exhibited a higher frequency of CD30 positivity (25.0% versus 8.1%, respectively; P